Reaction
Small Cell Lung Cancer reporting signals
As of the last recalculation, Small Cell Lung Cancer appears in 1,442 FAERS reports alongside 21 co-occurring drug terms. The strongest observed disproportionality signal is GEFITINIB (PRR 50.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Gefitinib | 31 | 50.6 | 50.8 |
| Atezolizumab | 82 | 32.3 | 32.3 |
| Osimertinib | 56 | 26.2 | 26.2 |
| Etoposide | 118 | 25.1 | 25.2 |
| Erlotinib | 15 | 22.6 | 22.6 |
| Erlotinib Hydrochloride | 16 | 18.7 | 18.7 |
| Baricitinib | 12 | 18.1 | 18.1 |
| Durvalumab | 21 | 15.1 | 15.1 |
| Carboplatin | 122 | 15.1 | 15.1 |
| Tolvaptan | 14 | 14.0 | 14.0 |
| Nintedanib | 29 | 13.6 | 13.6 |
| Pemetrexed | 19 | 12.9 | 13.0 |
| Cladribine | 6 | 9.0 | 9.0 |
| Cisplatin | 46 | 8.7 | 8.8 |
| Pemetrexed Disodium | 22 | 8.4 | 8.5 |
| Pirfenidone | 22 | 7.9 | 7.9 |
| Bleomycin Sulfate | 5 | 7.0 | 7.0 |
| Fluticasone Propionate And Salmeterol | 19 | 6.7 | 6.7 |
| Umeclidinium Bromide And Vilanterol Trifenatate | 7 | 6.1 | 6.1 |
| Obinutuzumab | 6 | 5.3 | 5.3 |
| Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate | 12 | 4.2 | 4.2 |